When it comes to football, there isn’t much Kendall Simmons hasn’t seen. Throughout his 45 years, MTSU’s second year ...

In a report released today, Jo Walton from UBS maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK750.00. The company’s shares closed yesterday at ...

In a report released today, James Quigley from Goldman Sachs maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a price target of DKK875.00. The company’s shares closed ...

LISBON, Jan 31 (Reuters) - U.S. private equity firm Lone Star has told the Portuguese government that it is likely to sell a 25-30% stake in Novo Banco via an initial public offering, rather than ...

That haul helped Novo’s total sales for 2024 grow 26% at constant currencies to 290.4 billion kroner (nearly $41 billion), contributing to operating profits of 128.3 billion kroner ($18 billion ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk emissions grew 23% in 2024, the company said on Wednesday, and will keep rising through the end of the decade as it boosts production of ...

Logo Myocene MYOCENE kicks off the first FDA De Novo clearance of 2025 for its groundbreaking muscle fatigue monitoring device. LIèGE, ...

In a fresh appearance on CNBC’s Squawk on the Street, Jim Cramer cautioned viewers to not be caught up by the energy that’s ...

Bagmatic NOVO is our new blood collection monitor serving the special needs of mobile blood donations. As a light weight device with outstanding long battery life, it is developed to take a ...

Inter Miami CF have signed goalkeeper Rocco Ríos Novo on loan for the 2025 MLS season from Argentine top-flight side Lanús, the club announced Thursday. A former Argentina youth international ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. Let’s get into all the earnings and political news ...